Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Treatment Sequencing and Efficacy in Newly Diagnosed Non-Transplant Eligible Myeloma Patients in the Netherlands: A Population Based Study

S GR Verelst, Y van Norden, H M Blommestein, J Roobol, M Schoenmaker, P. Sonneveld

Blood (2012) 120 (21): 4284.

https://doi.org/10.1182/blood.V120.21.4284.4284

Published: 2012

Journal Articles

Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial

S. Verelst, F. Termorshuizen, C. Uyl-de Groot, M. R Schaafsma, R. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman, M. van Marwijk Kooy, R. van der Griend, H. Lokhorst, P. Sonneveld, P. Wijermans

Blood (2010) 116 (21): 2972.

https://doi.org/10.1182/blood.V116.21.2972.2972

Published: 2010

Journal Articles

MicroRNA Profiling In Multiple Myeloma

Sophie Corthals, Su Ming Sun, Rowan Kuiper, Yvonne de Knegt, Annemiek Broyl, MD, Bronno van der Holt, H. Berna Beverloo, PhD, Justine K Peeters, Mark van Duin, PhD, Henk M Lokhorst, Sonja Zweegman, Mojca Jongen-Lavrencic, MD, PhD, P. Sonneveld

Blood (2010) 116 (21): 302.

https://doi.org/10.1182/blood.V116.21.302.302

Published: 2010

Journal Articles

High Incidence of Arterial Thrombosis in Young Patients Treated for Multiple Myeloma:Results of a Prospective Cohort Study.

Eduard J Libourel, P. Sonneveld, Bronno van der Holt, F. W.G. Leebeek, MD, PhD

Blood (2009) 114 (22): 149.

https://doi.org/10.1182/blood.V114.22.149.149

Published: 2009

Journal Articles

Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

P. Wijermans, M. Schaafsma, Y. van Norden, R. Ammerlaan, S. Wittebol, H. Sinnige, Sonja Zweegman, M. van Marwijk Kooi, R. Van der Griend, H. Lokhorst, P. Sonneveld

Blood (2008) 112 (11): 649.

https://doi.org/10.1182/blood.V112.11.649.649

Published: 2008

Journal Articles

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2008) 112 (11): 653.

https://doi.org/10.1182/blood.V112.11.653.653

Published: 2008

Journal Articles

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

B. Lowenberg, MD, F. Davies, MD, C. Müller-Tidow, MD, Ulrich Dührsen, A. Burnett, MD, FRCP, P. Zachée, MD, PhD, D. Dierickx, MD, C. Jenkins, MD, P. Sonneveld, MD, M. Jongen-Lavrencic, MD, S. Zweegman, MD, G. Morgan, MD, U. Krug, MD, A. Richardson, PhD, L. Hooftman, MD, G. Ossenkoppele, MD, PhD

Blood (2008) 112 (11): 961.

https://doi.org/10.1182/blood.V112.11.961.961

Published: 2008

Journal Articles

Gene Expression Profiles for Molecular Classification of Multiple Myeloma in Newly Diagnosed Patients Included in a Prospective, Multicenter, Phase 3 Trial.

A. Broyl, J. Peeters, D. Hose, Y. de Knegt, B. Beverloo, H. Lokhorst, H. Goldschmidt, M. van Duin, P. Sonneveld

Blood (2008) 112 (11): 1683.

https://doi.org/10.1182/blood.V112.11.1683.1683

Published: 2008

Journal Articles

Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant.

Shaji Kumar, MD, J. Blade, MD, J. San Miguel, MD, R. Hajek, MD, A. Nagler, MD, MSc, P. Sonneveld, MD, PhD, A. Spencer, DM, H.J. Sutherland, MD, PhD, T. Robak, MD, PhD, S.D. Mundle, PhD, S.H. Zhuang, MD, PhD, J.L. Harousseau, MD, R.Z. Orlowski, MD, PhD

Blood (2007) 110 (11): 2730.

https://doi.org/10.1182/blood.V110.11.2730.2730

Published: 2007

Journal Articles

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer, T. Facon, J. Harousseau, A. Boral, K.C. Anderson

Blood (2006) 108 (11): 3529.

https://doi.org/10.1182/blood.V108.11.3529.3529

Published: 2006

Journal Articles

All IPI Factors Are Equal, but LDH Is More Equal Than Others.

Gustaaf W. van Imhoff, MD, W. Graveland, B. Van der Holt, M. Van Glabbeke, PhD, L. F. Verdonck, MD, PhD, P. Sonneveld, MD, PhD, J. C. Kluin-Nelemans, MD, PhD

Blood (2005) 106 (11): 1913.

https://doi.org/10.1182/blood.V106.11.1913.1913

Published: 2005

Journal Articles

HuMax-CD20, a Novel Fully Human Anti-CD20 Monoclonal Antibody: Results of a Phase I/II Trial in Relapsed or Refractory Follicular Non-Hodgkins’s Lymphoma.

A. Hagenbeek, T. Plesner, P. Johnson, L. Pedersen, J. Walewski, A. Hellmann, B. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, M. Kneba, A. Engert, P. Sonneveld, J. Petersen, J. Radford

Blood (2005) 106 (11): 4760.

https://doi.org/10.1182/blood.V106.11.4760.4760

Published: 2005

Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3474.

https://doi.org/10.1182/blood.V106.11.3474.3474

Published: 2005

Journal Articles

Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.

Blood (2005) 106 (11): 3414.

https://doi.org/10.1182/blood.V106.11.3414.3414

Published: 2005

Journal Articles

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

J.F. San Miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 366.

https://doi.org/10.1182/blood.V106.11.366.366

Published: 2005

Journal Articles

Treatment with Arsenic Trioxide, Ascorbic Acid and Dexamethasone in Advanced Myeloma Patients: Preliminary Findings of a Multicenter, Phase II Study.

K. Wu, MD, J. van Droogenbroeck, MD, M. Beksac, MD, Y. de Knegt, P. Sonneveld, MD

Blood (2005) 106 (11): 5135.

https://doi.org/10.1182/blood.V106.11.5135.5135

Published: 2005

Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2004) 104 (11): 1479.

https://doi.org/10.1182/blood.V104.11.1479.1479

Published: 2004

Journal Articles

Complete Remission of t(11;17) Positive Acute Promyelocytic Leukemia Induced by All- trans Retinoic Acid and Granulocyte Colony-Stimulating Factor

J.H. Jansen, M.C. de Ridder, W.M.C. Geertsma, C.A.J. Erpelinck, K. van Lom, E.M.E. Smit, R. Slater, B.A. vd Reijden, G.E. de Greef, P. Sonneveld, B. Löwenberg

Blood (1999) 94 (1): 39–45.

https://doi.org/10.1182/blood.V94.1.39.413a26_39_45

Published: 1999

Journal Articles

Lung-Resistance–Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple Myeloma

H.G.P. Raaijmakers, M.A.I. Izquierdo, H.M. Lokhorst, C. de Leeuw, J.A.M. Belien, A.C. Bloem, A.W. Dekker, R.J. Scheper, P. Sonneveld

Blood (1998) 91 (3): 1029–1036.

https://doi.org/10.1182/blood.V91.3.1029

Published: 1998

NARROW

Treatment Sequencing and Efficacy in Newly Diagnosed Non-Transplant Eligible Myeloma Patients in the Netherlands: A Population Based Study

Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial

MicroRNA Profiling In Multiple Myeloma

High Incidence of Arterial Thrombosis in Young Patients Treated for Multiple Myeloma:Results of a Prospective Cohort Study.

Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

Gene Expression Profiles for Molecular Classification of Multiple Myeloma in Newly Diagnosed Patients Included in a Prospective, Multicenter, Phase 3 Trial.

Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant.

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

All IPI Factors Are Equal, but LDH Is More Equal Than Others.

HuMax-CD20, a Novel Fully Human Anti-CD20 Monoclonal Antibody: Results of a Phase I/II Trial in Relapsed or Refractory Follicular Non-Hodgkins’s Lymphoma.

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

Treatment with Arsenic Trioxide, Ascorbic Acid and Dexamethasone in Advanced Myeloma Patients: Preliminary Findings of a Multicenter, Phase II Study.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Complete Remission of t(11;17) Positive Acute Promyelocytic Leukemia Induced by All- trans Retinoic Acid and Granulocyte Colony-Stimulating Factor

Lung-Resistance–Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only